Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 6, 2012, Pages 592-597

  He, Zebao ^a   Wang, Jiefei ^b   Liu, Kezhou ^c   Huang, Haibin ^a   Du, Yao ^a   Lin, Zongmei ^d   Cai, Miaoguo ^d   Feng, Xinghua ^d  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC HEPATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DIZZINESS; DRUG COMBINATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADENINE; ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84870390803     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.05.012     Document Type: Article

References (13)

1. Melegari M., Scaglioni P.P., Wands J.R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998, 27:628-633.
2. He Y.W., Guo C.X., Pan Y.F., Li S.L., Wang H. The relationship between lamivudine therapy and the associated early clinical response and efficacy. Chin J Hepatol 2006, 14:902-905.
3. Yuen M.F., Fung J., Seto W.K., Wong D.K., Yuen J.C., Lai C.L. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Antivir Ther 2009, 14:679-685.
4. Yuen M.F., Sablon E., Hui C.K., Yuan H.J., Decraemer H., Lai C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34:785-791.
5. Locarnini S., Qi X., Arterburn S., et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005, 42(Suppl. 2):17.
6. Yuen M.F., Fung J., Seto W.K., Wong D.K., Yuen J.C., Lai C.L. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start andcontinue patients with lamivudine therapy. Antivir Ther 2009, 14:679-685.
7. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
8. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-1010.
9. Hui C.K., Zhang H.Y., Bowden S., Locarnini S., Luk J.M., Leung K.W., et al. 96weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008, 48:714-720.
10. Mao Y.M., Ceng M.D., Wei L. A 48-week, randomized, double-blind, parallel placebo-controlled, multi-center clinical trial of domestically-produced adefovir dipivoxil for the treatment of HBeAG-positive chronic hepatitis B. Liver 2007, 12:355-359.
11. Liu C.J., Huang W.L., Chen P.J., Lai M.Y., Kao J.H., Chen D.S. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. World J Gastroenterol 2004, 10:3574-3578.
12. Hass H.G., Bock T., Nehls O., Kaiser S. Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B. Gastroenterol 2009, 44:871-877.
13. Yokosuka O., Takaguchi K., Fujioka S., Shindo M., Chayama K., Kobashi H., et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol 2010, 52:791-799.